DFSSN

Dipartimento di
Farmacia e Scienze della Salute e della Nutrizione
Dipartimento di Eccellenza L. 232/2016

  • Dipartimento di Farmacia e Scienze della Salute e della Nutrizione

 

 
 

 

Dr Ivan CASABURI

 

education

2006 - Ph.D. in “Cell Biochemistry and Drug Action in Oncology” University of Calabria, Italy.

2003 - Specialist in Clinical Pathology – University of Calabria, Italy.

1996 - Master Degree in Biological Sciences – University of Perugia, Italy.

 

professional experience

2006 - present: Assistant Professor in General Pathology, Faculty of Pharmacy, Nutritional and Health Sciences, Department of Pharmaco-Biology, University of Calabria – Italy. Main focus: “Role of ERRα and GPER in Adrenocortical Cancer biology” “Leptin/Leptin Receptor signaling in Breast Cancer”, Alternate Estrogen receptor (GPR30) signaling in Testicular tumorogenesis”; Characterization and role of food component in cancer prevention”.

2002-2006: Post-doctoral fellowship in Sebastiano Andò Lab, Department of Pharmaco-Biology- University of Calabria, Italy. Main focus: “Estrogen and Androgen receptors signaling  in Breast Cancer growth and progression”, “Morpho-functional and biomolecular characterization of human ejaculated spermatozoa”;

2000-2002: Post-doctoral fellowship in Renato Baserga Lab, Kimmel Cancer Center, , Philadelphia, PA (USA). Main focus: “IGF-1R signaling in cancer biology”.

1998-2000: Post-doctoral fellowship in Sebastiano Andò Lab, Department of Pharmaco-Biology- University of Calabria, Italy. Main focus: “Aromatase and Breast cancer”.

1997: Endocrinology Fellowship in Riccardo Calafiore Lab, Department of Internal Medicine, University of Perugia. Main focus: xenotransplantation of microencapsulated Sertoli cells to cure human Type 1 Diabetes Mellitus "

 

managerial/department role

Responsible for the website, Master’s Degree Course in Pharmacy – link https://www.unical.it/portale/strutture/dipartimenti_240/dfssn/corsi_di_laurea_270/farmacia/

 

Reference teacher, Master’s Degree Course in Pharmacy - link

https://www.unical.it/portale/strutture/dipartimenti_240/dfssn/corsi_di_laurea_270/farmacia/docenti/

DOCENTI%20DI%20RIFERIMENTO2.pdf

 

research fields

MAIN RESEARCH INTEREST Adrenocortical carcinoma (ACC) is a rare and an extremely heterogeneous disease and its pathogenesis is considered to be a multi-molecular event making monotherapy and conventional therapeutic options ineffective. For these reasons new approaches never tested in ACC must be pursued. It is currently accepted that cancer-associated signaling pathways are also linked with reprogramming cellular metabolism. The orphan nuclear receptor known as the estrogen-related receptors (ERR) α subtype has been shown to regulate mitochondrial biogenesis and metabolic pathways involved in preserving cellular energy homeostasis and to meet the increased bioenergetics demand of cancerous cells. Our recent study demonstrated that the chemical depletion of ERRα using the inverse agonist XCT790, reduces mitochondrial functions and mass and inhibits adrenocortical cancer H295R cell growth both in vitro and in vivo. Intriguingly, we also showed that mitochondrial biogenesis is required for the anchorage independent survival and propagation of tumor initiating stem-like cells (TICs).

In adrenocortical cancer cells the nuclear receptor ERRα is a master regulator of reprogramming cellular metabolism that supports progression and determines cancer stem cell-like proprieties in ACC. Therefore, ERRα could be a new targetable therapeutic option to fight proliferation and invasion of ACC.

The aim of this project will be: 1. To ascertain the role of ERRα on ACC metabolic reprogramming focusing mainly on mitochondrial function evidencing the differences in metabolic program between normal adrenal cells and ACC cells. 2. To understand whether the metabolic role played by ERRα could also foster an invasive and metastatic trait in ACC cells. 3. To identify the role of ERRα in in determining and maintaining cancer stem cell-like properties in ACC. 4. To verify if XCT790 is an efficient drug to inhibit ACC progression.

Publications

https://orcid.org/0000-0001-7307-2492

teaching activity

A.A. 2006-2007 Molecular Pathology (7 CFU), course in Scientific Information on Drugs;

A.A. 2007-2009 General Pathology (5 CFU), course in Nutritional Science;

A.A. 2008-2012 General Physiopathology (7 CFU), course in Scientific Information on Drugs;

A.A. 2009-2017 Medical genetics, Specialization School in “Clinical Pathology

A.A. 2014-2016 Dietetics and Dietology (3 CFU), course in Pharmacy;

A.A. 2016-2020 General Physiopathology (3 CFU), course in Pharmacy;

A.A. 2017-2020 Dietetics and Dietology (6 CFU), course in Pharmacy.

 

Teaching Unit

Titolo del corso 1: Dietetica e Dietologia, corso di Laurea in Farmacia - Dietetics and Dietology, Master’s Degree Course in Pharmacy (Link: https://www.unical.it/portale/strutture/dipartimenti_240/dfssn/areastudenti/avvisi_docenti/casaburi/)

Titolo del corso 2: Fisiopatologia Generale, corso di Laurea in Farmacia - General Physiopathology, Master’s Degree Course in Pharmacy; (Link: https://www.unical.it/portale/strutture/dipartimenti_240/dfssn/areastudenti/avvisi_docenti/casaburi/ )